WUH: MYK-461-005(EXPLORER-HCM): A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Brief description of study

The purpose of this study is to understand the effect of an investigational drug, mavacamten, compared to a placebo (an inactive drug) in patients with obstructive Hypertrophic Cardiomyopathy. This is being done to confirm that mavacamten is safe, and can be tolerated in HCM and to study whether it helps to improve symptoms or ability to exercise. Mavacamten is an investigational drug, referred to as study drug in this consent form. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of HCM.

Clinical Study Identifier: s18-01644
ClinicalTrials.gov Identifier: NCTs18-01644